Evidence map›Paper›PMID 30045572›Full record

ReviewThe Science of the total environment2018

Harvesting the promise of AOPs: An assessment and recommendations.

Annamaria Carusi, Mark R Davies, Giovanni De Grandis, Beate I Escher, Geoff Hodges, Kenneth M Y Leung, Maurice Whelan, Catherine Willett, Gerald T Ankley

Abstract readReview
In one paragraph

Review in The Science of the total environment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. New approach methodologies (NAMs) for theFrontiers in toxicology · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Are Non-animal Systemic Safety Assessments Protective? A Toolbox and Workflow.Toxicological sciences : an official journal of the Society of Toxicology · 2022
    Article
  14. Article
  15. Adverse Outcome Pathways as Versatile Tools in Liver Toxicity Testing.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  16. Article
  17. Overview of Adverse Outcome Pathways and Current Applications on Nanomaterials.Advances in experimental medicine and biology · 2022
    Review
  18. Article
  19. Review
  20. A Pragmatic Approach to Adverse Outcome Pathway Development and Evaluation.Toxicological sciences : an official journal of the Society of Toxicology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Annamaria CarusiMedical Humanities Sheffield, University of Sheffield, Medical School, Beech Hill Road, Sheffield S10 2RX, UK. Electronic address: a.carusi@sheffield.ac.uk.
Mark R DaviesQT Informatics Limited, Macclesfield SK10 5DS, UK. Electronic address: mark.davies@qtinformatics.com.
Giovanni De GrandisScience, Technology, Engineering and Public Policy (STEaPP), Boston House, 36-37 Fitzroy Square, London W1T 6EY, UK. Electronic address: g.degrandis@ucl.ac.uk.
Beate I EscherUFZ - Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany; Eberhard Karls University Tübingen, Environmental Toxicology, Centre for Applied Geosciences, 72074 Tübingen, Germany. Electronic address: beate.escher@ufz.de.
Geoff HodgesSafety and Environmental Assurance Centre, Unilever, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK. Electronic address: geoff.hodges@unilever.com.
Kenneth M Y LeungThe Swire Institute of Marine Science and School of Biological Sciences, The University of Hong Kong, Pokfulam, Hong Kong, China. Electronic address: kmyleung@hku.hk.
Maurice WhelanEuropean Commission, Joint Research Centre (JRC), Ispra, Italy. Electronic address: maurice.whelan@ec.europa.eu.
Catherine WillettThe Humane Society of the United States, 700 Professional Drive, Gaithersburg, MD, 20879, USA. Electronic address: kwillett@humanesociety.org.
Gerald T AnkleyUS Environmental Protection Agency, 6201 Congdon Blvd, Duluth, MN 55804, USA. Electronic address: ankley.gerald@epa.gov.

Funding

Wellcome Trust
6 · The paper itself

Abstract

The Adverse Outcome Pathway (AOP) concept is a knowledge assembly and communication tool to facilitate the transparent translation of mechanistic information into outcomes meaningful to the regulatory assessment of chemicals. The AOP framework and associated knowledgebases (KBs) have received significant attention and use in the regulatory toxicology community. However, it is increasingly apparent that the potential stakeholder community for the AOP concept and AOP KBs is broader than scientists and regulators directly involved in chemical safety assessment. In this paper we identify and describe those stakeholders who currently-or in the future-could benefit from the application of the AOP framework and knowledge to specific problems. We also summarize the challenges faced in implementing pathway-based approaches such as the AOP framework in biological sciences, and provide a series of recommendations to meet critical needs to ensure further progression of the framework as a useful, sustainable and dependable tool supporting assessments of both human health and the environment. Although the AOP concept has the potential to significantly impact the organization and interpretation of biological information in a variety of disciplines/applications, this promise can only be fully realized through the active engagement of, and input from multiple stakeholders, requiring multi-pronged substantive long-term planning and strategies.

Indexed as

Adverse outcomes pathwaysChemical managementEnvironmental healthRisk assessmentSocial, ethical and legal aspectsToxicology

Identifiers

PMID30045572
PMCPMC5888775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.